Management of Hepatitis C Infection
Summary
- Efficacy of HCV treatment varies by HCV genotype and fibrosis stage
- Some newer DAAs have activity against multiple or all genotypes Ledipasvir/Sofosbuvir
- All 3 phase III ION trials demonstrated high SVR rates with ledipasvir/sofosbuvir with or without ribavirin when administrated for 8, 12, or 24 weeks in patients with genotype 1 HCV infection
- Ledipasvir/Sofosbuvir
Action required
- Login now to access all of your entitled content
or - View additional options to gain access to this content
Keywords: Hepatitis C-Treatment